Ventoux Biosciences

Modulating Fibrosis, Restoring Function

https://wefunder.com/ventoux.biosciences

Total raised on Wefunder: 0

Total investors: 0

Quick facts

  • Founded by a Dupuytren's patient to transform care for millions with immune-fibrotic diseases
  • Targeting Dupuytren's and Spinal Cord Injury with VEN-201, a novel, immune-fibrotic modulator
  • VEN-201 rebalances the immune system to reduce fibrosis and activate repair
  • 2025 Pre-Clinical Biopharmaceutical Company of the Year Winner, by GHP Biotechnology Awards
  • $4.3B Dupuytren's disease market, >3x larger than Rheumatoid Arthritis - no approved treatments
  • SCI: ~$10B annually, VEN-201 targets fibrosis, addressing the key market opportunity in recovery
  • Strong IP: Broad immune-fibrotic patent to 2044, global filings plus key provisional filings

Team profiles

Featured investor profiles

Ventoux Biosciences

Modulating Fibrosis, Restoring Function

$13,750

of a $50,000 goal
INVESTMENT TERMS
Future Equity
$13M valuation cap

What Investors Say

LEAD INVESTOR
Invested $70,000 this round + $30,000 previously
Ventoux is a founder-led biotech with a purpose and a mission that I strongly support. Kurt’s personal journey gives Ventoux an unmatched focus and sense of urgency. From an investor perspective, I was drawn to the blend of a a clear clinical strategy and initial evidence combined with the personal insight of a lived experience. Kurt and Ventoux are developing a platform that will be a game-changer and provide solutions for many people. I am in!
What People Say